Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports
Private equity firm Carlyle Group is preparing to offload up to a 10% stake in India's Piramal Pharma , online news portal Moneycontrol reported on Thursday, citing sources.
Fiscal Year: January - December
The Carlyle Group Inc. (CG), listed on the NASDAQ, has a market capitalization of $. As of Jul 05, 2025, the stock is trading at $55.70 per share, offering investors a clear view of its current market value. The Carlyle Group Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 18.92, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. The Carlyle Group Inc. also offers a dividend yield of 2.51%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that The Carlyle Group Inc. (CG) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for The Carlyle Group Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for The Carlyle Group Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for The Carlyle Group Inc. is 0, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, The Carlyle Group Inc. (CG) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether The Carlyle Group Inc. (CG) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of The Carlyle Group Inc. (CG) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of The Carlyle Group Inc.. To access the full SS Score, consider upgrading your subscription.
The Carlyle Group Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 18.92. Investors should compare these metrics with industry peers to gauge whether The Carlyle Group Inc. is outperforming or underperforming within its sector.
Private equity firm Carlyle Group is preparing to offload up to a 10% stake in India's Piramal Pharma , online news portal Moneycontrol reported on Thursday, citing sources.
MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial health...
The military industrial complex has pushed technology to continue to improve, and it is this defense-driven innovation that has given Silicon Valley its edge says Jeff Currie, Chief Strategy Officer o...
The asset-backed financing deal will support acquisitions by the natural-gas producer.
Jason Thomas, Carlyle head of global research and investment strategy, joins 'Squawk Box' to discuss the latest market trends following Washington's surprise strikes on Iran, state of the economy, the...
Private equity funds, including Carlyle and Triton, are weighing bids for Germany-based industrial equipment maker REMA Tip Top, which is exploring a possible sale, three people familiar with the matt...
Citigroup and Carlyle Group have reportedly joined forces to fund FinTech companies. [contact-form-7] As Bloomberg News reported Thursday (June 12), the companies have signed an agreement that lets th...
Investment firm Carlyle Group has partnered with U.S. banking giant Citigroup to provide asset-backed financing to fintech lenders, the companies said on Thursday.
Insurance brokerage firm Trucordia has secured a $1.3 billion investment from Carlyle through a deal that valued the company at $5.7 billion, it said on Wednesday.
Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK , June 4, 2025 /PRNewswire/ -- Trucordia today announced it ...
The firm's latest equity investment through its Credit Opportunities strategy values Trucordia at $5.7 billion.
AlpInvest Partners has raised $4.1 billion for its ninth co-investment fund, an executive at the unit of private equity group Carlyle said, showing continued appetite among investors for access to buy...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by gl...
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer comme...
Carlyle Group offers value with shares 20% below highs, strong AUM growth, and a secure 3.2% dividend yield. Fee-based earnings are highly predictable, with $26B pending fee-earning AUM and credible 6...
Establishes nitinol input tube operation to support premium, implant-grade tubing initiative and strengthen supply chain resilience NASHUA, N.H. , May 19, 2025 /PRNewswire/ -- Resonetics® announced to...
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...
U.S. private equity group Carlyle Group is expected to clinch in the coming days an accord to sell Italian fashion brand Twinset to local investment firms Borletti Group and Quadrivio, two sources clo...
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their ...
The Carlyle Group, Inc. (NASDAQ:CG) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Daniel Harris - Partner & Head, Public Investor Relations Harvey Schwartz - CEO & Dire...
Global investment firm Carlyle Group posted a 5.6% growth in first-quarter profit on Thursday, helped by higher fees as its assets under management climbed to a record.
Mark Jenkins, head of global credit at Carlyle Group, called the tariffs “temporary noise,” and said they're accelerating trends that had already begun post-Covid, like reshoring of supply chains and ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings...
Harvey Schwartz, CEO of the Carlyle Group, says his firm is actively seeking opportunities to deploy some of the firm's $80 billion in free capital into new investments.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | -621.75M | -25.74% | Est @-25.7% |
2026 | -406.29M | -34.65% | Analyst x2 |
2027 | 4,327.48M | -1,165.12% | Analyst x2 |
2028 | -428.00M | -109.89% | Analyst x1 |
2029 | 4,393.00M | -1,126.40% | Analyst x1 |
2030 | 5,351.77M | 21.83% | Est @21.8% |
2031 | 6,204.71M | 15.94% | Est @15.9% |
2032 | 6,938.11M | 11.82% | Est @11.8% |
2033 | 7,557.85M | 8.93% | Est @8.9% |
2034 | 8,045.64M | 6.45% | Est @6.5% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 138.30M | 1.00 | 138.30M |
2024A | -837.20M | 1.00 | -837.20M |
2025E | -621.75M | 1.10 | -564.99M |
2026E | -406.29M | 1.21 | -335.51M |
2027E | 4.33B | 1.33 | 3.25B |
2028E | -428.00M | 1.47 | -291.86M |
2029E | 4.39B | 1.61 | 2.72B |
2030E | 5.35B | 1.78 | 3.01B |
2031E | 6.20B | 1.95 | 3.18B |
2032E | 6.94B | 2.15 | 3.23B |
2033E | 7.56B | 2.37 | 3.19B |
2034E | 8.05B | 2.60 | 3.09B |
Terminal | 109.31B | 2.60 | 41.97B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.